Bordetella bronchiseptica is a potent and safe adjuvant that enhances the antigen-presenting capability of dendritic cells
10.4196/kjpp.2020.24.1.47
- Author:
You Jeong LEE
1
;
Yong HAN
;
Hong Gu JOO
Author Information
1. College of Veterinary Medicine, Jeju National University, Jeju 63243, Korea. jooh@jejunu.ac.kr
- Publication Type:Original Article
- Keywords:
Bordetella bronchiseptica;
Dendritic cells;
Immunostimulation;
Safety;
Vaccines
- MeSH:
Bacterial Vaccines;
Bordetella bronchiseptica;
Bordetella;
Cytokines;
Dendritic Cells;
Flow Cytometry;
Immunization;
Major Histocompatibility Complex;
Mycoplasma hyopneumoniae;
Survival Rate;
Vaccines
- From:The Korean Journal of Physiology and Pharmacology
2020;24(1):47-52
- CountryRepublic of Korea
- Language:English
-
Abstract:
We previously demonstrated that Bordetella bronchiseptica (B. bronchiseptica) antigen (Ag) enhances the Mycoplasma hyopneumoniae Ag-specific immune response. The focus of this study was whether acellular bacterin of B. bronchiseptica could be used as an adjuvant to increase antigen-presenting capability of dendritic cells (DCs) by increasing the level of activation. The metabolic activity of DCs was increased by B. bronchiseptica, similar to lipopolysaccharide (LPS). Flow cytometry analysis revealed that B. bronchiseptica increases the expression of major histocompatibility complex class-2, cluster of differentiation (CD)40, CD54, and CD86 which are closely related to DC-mediated immune responses. B. bronchiseptica enhanced the production of cytokines related to adaptive immune responses. Furthermore, the survival rate of B. bronchiseptica-injected groups was 100% at 15 and 20 mg/kg doses, whereas that of LPS-injected groups was only 20%, 0% at 15 and 20 mg/kg doses respectively, and so B. bronchiseptica is likely to be safer than LPS. Taken together, these results indicate that B. bronchiseptica can be used as an adjuvant to enhance the antigen-presenting capability of DCs. B. bronchiseptica is a candidate for producing vaccines, especially in case of DC-mediating efficacy and safety demands. This study provides researchers and clinicians with valuable information regarding the usage of B. bronchiseptica as a safe bacteria-derived immunostimulating agent for developing efficient vaccines.
